- The trend backdrop is active with a 50-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Next-week expectancy is positive at 57.04% based on similar historical setup states.
CGON
NASDAQ
Week ended 07 Aug 2026
Weekly Investor Report
CG Oncology, Inc. Common stock · Healthcare · Biotechnology
Latest close
75.10 USD
5.5%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 17.3% above the Trend Line and sits at 96.4% of its 52-week range. The latest completed week returned 5.5%, after a -0.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 46/100 conviction, while the latest news-sentiment score is 47/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal; earnings are due in 0d.
Setup score
67
out of 100
Latest Close
75.10 USD
7 Aug 2026
1W Return
5.5%
latest completed week
4W Return
-0.2%
short-term follow-through
12W Return
12.2%
quarterly tape
Trend Breadth
96.2%
50 of 52 weeks active
Volume Ratio
0.8x
vs 13-week average
- Activity pressure is negative, which weakens the current setup.
- 11 reversal markers appear in the recent smart-money tape.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
5.5%
Latest completed week; four-week move -0.2%.
Indicator stack
98/53
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Positive 57.04%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
46/100 conviction; expected move 9.2%.
News sentiment
47/100
43 relevant articles in the latest sentiment read.
Event risk
0d
Next report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 17.3% above the Trend Line and sits at 96.4% of its 52-week range. The latest completed week returned 5.5%, after a -0.2% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.6212-week average 0.73
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure1/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.62Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers1111 reversal markers
No recent accumulation markers. 11 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -0.2% over four weeks, 12.2% over 12 weeks, and 202.2% over one year. The current trend has remained active for 50 consecutive weeks.
Performance by holding period
Active trend streak50 weeks
Active weeks in one year50
Trend breadth96.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.13Latest activity-pressure read.
Pressure change60.7%Four-week change in activity pressure.
Leadership24.28Latest relative-leadership reading.
RS change-21.5%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 30 Jun 2026
Field coverage 82%
Model confidence 82%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength70/100Blend of value, momentum, and quality. Underlying universe rank 31; rank 1 is best.
Value60/100Relative valuation strength. Underlying universe rank 41; rank 1 is best.
Quality57/100Profitability and accounting quality. Underlying universe rank 44; rank 1 is best.
Momentum60/100Medium-term price momentum. Underlying universe rank 41; rank 1 is best.
Growth60/100Revenue and earnings growth. Underlying universe rank 41; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 1068.9x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -3.5% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- -82.7% Gross profit retained from each unit of revenue.
- Operating margin
- -3720.6% Operating profit retained from revenue.
- Free-cash-flow margin
- -3760.9% Free cash flow generated from revenue.
- Return on invested capital
- -17.1% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -8.1% Net share repurchases relative to market value.
- Shareholder yield
- -8.1% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
CGON shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 2.02, expected move of 9.2%, and Sharemaestro trend signal active.
Conviction46/100
Expected move9.2%
Put/call volume2.02
Insider activity-
No recent insider transactions are stored for this company.
News sentiment47/100
Weighted news tone is neutral across 43 relevant articles.
4 positive · 27 neutral · 12 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings0dNext report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
Options expected move9.2%Nearest-chain priced movement where available.
52-week drawdown-2.5%Distance below the 52-week high.
13-week volatility7.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher16 of 2610 weeks finished lower.
Best week+17.8%Week of 26 Jun.
Worst week-13.8%Week of 5 Jun.
Latest week+5.5%Week of 7 Aug.
Shape of recent returns
Strong gains9
Modest gains7
Flat weeks0
Modest losses6
Sharp losses4
Recent vol7.8%13-week weekly-return volatility.
Base vol7.4%52-week weekly-return volatility.
Up/down split32/20Count of positive and negative weeks in the 52-week window.
Average skew6.4% / -4.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average2.6%
Trend breadth54.0%
Trend54.0%active weekly trend signals
MD77.0%positive activity pressure
RS44.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank53 / 100
Group average0.5%
Trend breadth70.0%
Trend70.0%active weekly trend signals
MD64.0%positive activity pressure
RS62.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape70/100
Trend, activity pressure, participation, and risk combine to a 70/100 tape read.
Indicator analysis57/100Latest 12-week confirmation: trend 12/12, activity pressure 1/12, relative leadership 12/12.
Activity pressure 0.62; 11 reversal markers Next-Week ExpectancyPositive 57.04%Next-week expectancy is positive with a 57.04% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors61/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 85; Small Cap Core rank 47 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options55/100CGON shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 2.02, expected move of 9.2%, and Sharemaestro trend signal active.
Volatility · Volatility expansion watch · Expected move 9.2% Sentiment47/100Weighted news tone is neutral across 43 relevant articles.
CGON (NASDAQ: CGON) holder files to sell 32,137 shares after option exercise Insiders50/100No recent insider transaction evidence is stored.
Earnings0dNext report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 75.10 USD | 5.5% | 64.03 USD | 40.43 USD | -0.13 | 24.28 | 4.0M | On |
| 31 Jul 2026 | 71.19 USD | 2.7% | 63.33 USD | 40.17 USD | -0.18 | 25.56 | 4.6M | On |
| 24 Jul 2026 | 69.32 USD | -3.5% | 62.35 USD | 39.93 USD | -0.25 | 24.55 | 3.8M | On |
| 17 Jul 2026 | 71.85 USD | -4.5% | 61.37 USD | 39.71 USD | -0.09 | 28.71 | 5.7M | On |
| 10 Jul 2026 | 75.24 USD | 6.9% | 60.27 USD | 39.46 USD | -0.33 | 30.92 | 4.7M | On |
| 3 Jul 2026 | 70.36 USD | -2.2% | 59.13 USD | 39.18 USD | -0.58 | 26.34 | 4.4M | On |
| 26 Jun 2026 | 71.96 USD | 17.8% | 58.23 USD | 38.93 USD | -0.78 | 31.96 | 9.9M | On |
| 19 Jun 2026 | 61.08 USD | 2.6% | 57.32 USD | 38.67 USD | -1.05 | 8.43 | 4.6M | On |
| 12 Jun 2026 | 59.56 USD | 10.9% | 56.70 USD | 38.49 USD | -0.97 | 9.50 | 4.6M | On |
| 5 Jun 2026 | 53.72 USD | -13.8% | 56.08 USD | 38.32 USD | -0.67 | 1.91 | 4.6M | On |
| 29 May 2026 | 62.29 USD | -3.1% | 55.62 USD | 38.20 USD | -0.20 | 13.58 | 4.6M | On |
| 22 May 2026 | 64.25 USD | -4.0% | 54.98 USD | 38.00 USD | 0.18 | 21.64 | 4.2M | On |
| 15 May 2026 | 66.93 USD | -3.9% | 54.30 USD | 37.78 USD | 0.60 | 29.59 | 5.6M | On |
| 8 May 2026 | 69.62 USD | 5.1% | 53.45 USD | 37.54 USD | 0.97 | 35.99 | 3.8M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.